We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low Serum Creatinine Associated with Diabetes Risk

By LabMedica International staff writers
Posted on 02 May 2019
Print article
Image: Low serum creatinine is associated with the risk of diabetes (Photo courtesy of Jo Lewin).
Image: Low serum creatinine is associated with the risk of diabetes (Photo courtesy of Jo Lewin).
Creatinine is the only metabolite of creatine phosphate in the skeletal muscle and under the steady state; it is created at a relatively constant rate by the body depending on the total skeletal muscle mass.

Because of the close association between muscle mass and creatinine (correlation coefficient equal to or greater than 0.7), serum creatinine is also used as an inexpensive, easily available surrogate of muscle mass when the kidney functions are stable and protein intake is normal.

Scientists at the National Center for Global Health and Medicine (Tokyo, Japan) and their colleagues conducted a prospective analysis using data from 31,343 men aged between 20 to 64 years without diabetes at baseline from the Japan Epidemiology Collaboration on Occupational Health Study. Participants were followed for a median of 7.7 years until March 2017 and separated into four groups based on baseline serum creatinine levels: less than 0.7 mg/dL (n = 1,492; mean age, 44.9 years), 0.7 mg/dL to 0.79 mg/dL (n = 6,405; mean age, 42.6 years), 0.8 mg/dL to 0.89 mg/dL (n = 10,848; mean age, 42.1 years) and 0.9 mg/dL to 1.2 mg/dL (n = 12,598; mean age, 43.6 years).

The team assessed the levels of serum creatinine using the enzymatic method and identified 2,509 cases of diabetes in the study cohort. The plasma glucose was measured using either the enzymatic or glucose oxidase peroxidative electrode method. HbA1c was measured using a latex agglutination immunoassay, high-performance liquid chromatography, or the enzymatic method. They defined diabetes as either HbA1c levels ≥6.5%, random glucose levels ≥200 mg/dL, fasting glucose levels ≥126 mg/dL or receiving antidiabetic treatment. The participants who met any of the aforementioned conditions during follow up were treated as incident cases of type 2 diabetes.

Men with serum creatinine levels of less than 0.7 mg/dL were at the highest risk for the condition (HR = 1.56)) compared with men with levels of 0.9 mg/dL to 1.2 mg/dL even after adjustments for age, smoking status, BMI, hypertension and dyslipidemia. Men with serum creatinine levels of 0.7 mg/dL to 0.79 mg/dL (HR = 1.22 and 0.8 mg/dL to 0.89 mg/dL (HR = 1.06) also were at higher fully adjusted risk compared with men with levels of 0.9 mg/dL to 1.2 mg/dL. The scientists further observed that men who were aged 45 years or older had higher risk in all creatinine groups compared with men who were younger than 45 years.

The team concluded that in their study based on repeated measurements of serum creatinine shows that low serum creatinine is associated with an increased risk of diabetes. Screening serum creatinine levels can be used to identify those at a high risk of diabetes. Huanhuan Hu, PhD, the lead author of study, said, “Skeletal muscle is a primary target for insulin action. Thus, decreased skeletal muscle mass could potentially trigger insulin resistance, which is an underlying mechanism of diabetes.” The study was published originally published on February 12, 2019, in the Journal of Diabetes Investigation.

Related Links:
National Center for Global Health and Medicine

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.